No Data
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $164
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
10 Health Care Stocks With Whale Alerts In Today's Session
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Express News | Market news: Viking Therapeutics has achieved multiple endpoints in the Nash/Mash Phase 2B clinical trial results.